On 30 June 2026, Skyhawk Therapeutics shared further 12-month data from the ongoing phase 1/2 trial of SKY-0515 (also being tested in the EHDN-endorsed phase 2/3 study). Utilising a propensity score-weighted comparison – using Enroll-HD and TRACK-HD natural history datasets – favourable and consistent trends for participants receiving SKY-0515 were found across the four cUHDRS subcomponents. Skyhawk also shared 12-month data from the Clinician and Patient Global Impression of Change surveys, indicating an absence of clinician- and patient-assessed disease progression.

Read the 1 June and 30 June press releases and HDBuzz’s commentary.

Click here for details of all ongoing and completed EHDN-endorsed studies.